Christopher A. Viehbacher has been the CEO of Biogen since November 2022, stepping in at a critical time for the company. With a strong background in healthcare, having previously served as Global CEO of Sanofi, he knows the industry well....

Christopher A. Viehbacher has been the CEO of Biogen since November 2022, stepping in at a critical time for the company. With a strong background in healthcare, having previously served as Global CEO of Sanofi, he knows the industry well. He co-founded Gurnet Point Capital and led various initiatives at Biogen when he arrived, aiming to realign the company's focus and strategy. His work has driven the launch of new therapies like LEQEMBI, helping to address significant health challenges. With a B.Comm from Queen's University and being a Chartered Accountant, Viehbacher combines business acumen with a passion for healthcare.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Biogen CEOs

B

Christopher A. Viehbacher

CEO of Biogen

Education

B. Comm from Queen's University

Field of Expertise

Healthcare & Life Sciences - Healthcare

Sector of Economy

Healthcare

Born

January 1, 1960 - 65 years ago

CEO of Biogen for

2 years 6 months (Nov 2022 - Present)

Previous Experience

Managing Partner at Gurnet Point Capital, former Global CEO at Sanofi

Rivals

Competitors/colleagues of Christopher A. Viehbacher

G

Daniel O'Day

CEO of Gilead Sciences

2023 Compensation

Stock

$16.51M

Salary

$1.74M

Bonus

$0.00

Other

$1.22M

Total Holdings

$103.20M

M

Stéphane Bancel

CEO of Moderna

2023 Compensation

Stock

$0.00

Salary

$1.58M

Bonus

$1.91M

Other

$1.07M

Total Holdings

$491.74M

B

Christopher Boerner

CEO of Bristol-Myers Squibb

2023 Compensation

Stock

$0.00

Salary

$1.50M

Bonus

$0.00

Other

$311.64K

Total Holdings

$22.05M

V

Reshma Kewalramani

CEO of Vertex Pharmaceuticals

2022 Compensation

Stock

$10.64M

Salary

$1.40M

Bonus

$3.78M

Other

$43.06K

Total Holdings

$54.25M

A

Robert A. Bradway

CEO of Amgen

2023 Compensation

Stock

$0.00

Salary

$1.79M

Bonus

$0.00

Other

$680.46K

Total Holdings

$182.86M

I

Brett P. Monia, Ph.D.

Founder and CEO of Ionis Pharmaceuticals

2023 Compensation

Stock

$430.00K

Salary

$650.00K

Bonus

$300.00K

Other

$50.00K

Total Holdings

$5.97M

Holdings

See how much did Christopher A. Viehbacher make over time.

As of 2023, Christopher A. Viehbacher holds a significant investment in Biogen Inc. Common Stock (BIIB). His focus has fluctuated, especially following his appointment as CEO in late 2022, when he committed to buying at least $2 million in company...

As of 2023, Christopher A. Viehbacher holds a significant investment in Biogen Inc. Common Stock (BIIB). His focus has fluctuated, especially following his appointment as CEO in late 2022, when he committed to buying at least $2 million in company stock. Despite not being granted any equity in 2023, his involvement with the stock has remained key to his leadership strategy. The total value of his holdings reflects the company’s performance goals, which he actively shapes, as indicated by his aim to realign the company and cut $1 billion in costs by 2025, emphasizing long-term stockholder value.

Mar 18, 2025

B

shares

BIIB @ $143.09

R

shares

RVTY @ $112.69

Insider Trading

See recent insider trades of Christopher A. Viehbacher.

RVTY

2,195 shares

RVTY

May 1, 2024

Received

RVTY

1,738 shares

RVTY

May 15, 2023

Received

BIIB

10,594 shares

BIIB

Jan 19, 2022

Received

BIIB

16,343 shares

BIIB

Jan 27, 2021

Received

BIIB

$748.05K

BIIB at $241.31/share

Nov 30, 2020

Purchase

BIIB

$1.01M

BIIB at $231.48/share

May 1, 2019

Purchase

BIIB

$250.03K

BIIB at $320.55/share

Dec 29, 2017

Purchase

BIIB

$380.43K

BIIB at $271.35/share

May 1, 2017

Purchase

BIIB

$380.42K

BIIB at $285.39/share

Feb 27, 2017

Purchase

Compensation History

See how much did Christopher A. Viehbacher make over time.

In 2023, Christopher A. Viehbacher's total compensation was $3,976,000. His salary was $1,600,000, which stayed the same as the year before. He also received a bonus of $2,376,000. This bonus was linked to the company’s performance goals and his individual goals, showcasing a results-driven approach. Notably, he did not receive any stock grants or vested stock this year, indicating a strategic focus on direct cash bonuses instead of long-term equity. This compensation structure emphasizes performance, aligning with Biogen's plans for growth and cost savings over the next few years.

Year

2023

Total Compensation

$3.98M

Salary

$1.60M

Board Justification

The compensation philosophy is to reward executives for the creation of long-term stockholder value, with a focus on performance-based compensation that is competitive with peer groups to attract and retain leaders.

Bonus

$2.38M

Board Justification

The annual bonus for Mr. Viehbacher was based on the achievement of company performance goals and individual performance goals, with a company multiplier of 99% and an individual multiplier of 100%.

Other

$0.00

Board Justification

No additional compensation was reported for Mr. Viehbacher in 2023.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was granted or vested in 2023 as Mr. Viehbacher was not eligible for LTI grants in 2023.

Performance Metrics

The performance metrics for Mr. Viehbacher's compensation included company financial performance and individual performance goals.

Other Biogen CEOs

Here are other CEOs of Biogen

Michel Vounatsos

Ex-CEO of Biogen

July 2016 - November 2022